VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Update

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 1,791,894 shares, an increase of 40.6% from the November 30th total of 1,274,319 shares. Based on an average daily volume of 992,442 shares, the short-interest ratio is presently 1.8 days. Approximately 4.7% of the shares of the company are sold short. Approximately 4.7% of the shares of the company are sold short. Based on an average daily volume of 992,442 shares, the short-interest ratio is presently 1.8 days.

VistaGen Therapeutics Trading Down 9.4%

Shares of VTGN stock opened at $0.66 on Tuesday. The stock has a 50 day simple moving average of $3.60 and a 200-day simple moving average of $3.22. The company has a market cap of $26.06 million, a price-to-earnings ratio of -0.35 and a beta of 0.56. VistaGen Therapeutics has a 12-month low of $0.65 and a 12-month high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its earnings results on Thursday, November 13th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The business had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.16 million. On average, equities analysts forecast that VistaGen Therapeutics will post -1.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

VTGN has been the subject of several recent research reports. Jefferies Financial Group reiterated a “hold” rating and set a $0.90 target price (down previously from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Wall Street Zen cut VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Stifel Nicolaus downgraded VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price on the stock. in a research note on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, October 8th. Finally, Maxim Group reiterated a “hold” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, VistaGen Therapeutics presently has an average rating of “Reduce” and an average target price of $0.95.

Institutional Trading of VistaGen Therapeutics

Several large investors have recently bought and sold shares of VTGN. ADAR1 Capital Management LLC raised its stake in shares of VistaGen Therapeutics by 246.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company’s stock worth $1,052,000 after buying an additional 299,304 shares during the last quarter. AdvisorShares Investments LLC increased its holdings in VistaGen Therapeutics by 27.7% during the 2nd quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company’s stock valued at $406,000 after acquiring an additional 44,000 shares in the last quarter. GSA Capital Partners LLP acquired a new position in VistaGen Therapeutics during the third quarter worth about $112,000. Millennium Management LLC purchased a new stake in shares of VistaGen Therapeutics in the third quarter valued at about $73,000. Finally, Bank of America Corp DE grew its position in shares of VistaGen Therapeutics by 926.0% in the third quarter. Bank of America Corp DE now owns 34,657 shares of the company’s stock valued at $123,000 after purchasing an additional 31,279 shares during the last quarter. Institutional investors and hedge funds own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.